The NM_000152.5:c.692+5G>T variant in GAA is located in intron 3 and is predicted to disrupt the 5' donor splice site of the intron. At least 6 individuals have been reported with this variant and late-onset Pompe disease, including individuals with documented GAA enzyme deficiency and symptoms consistent with LOPD and receiving enzyme replacement therapy (PMIDs: 24384324, 26873529,27408821,29181627, 30155607). At least three individuals with confirmed Pompe disease are compound heterozygous for this variant and a second pathogenic variant (phase unconfirmed) including c.1076-22T>G (PMID: 27408821 ), c.953T>C (PMIDs: 3015560 and 29181627), and c.482_483del (PMID: 26873529) (PM3_strong). One individual with LOPD was reported to have this variant and c.1211A>G, classified as likely pathogenic by the ClinGen Lysosomal Diseases VCEP; however, points were not given for PP4 or PM3 to avoid circular logic as data from this publication were used to support the classification of c.1211A>G (PMID: 2438432). The highest population minor allele frequency in gnomAD v4.1.0 is 0.00001195 (14/1171164 alleles) in the European non-Finnish population which is lower than the ClinGen LSD VCEP’s threshold for PM2_Supporting (<0.001), meeting this criterion (PM2_Supporting). The computational splicing predictor SpliceAI gives a score of 0.54 for donor loss, predicting that the variant disrupts the donor splice site of intron 3 of GAA (PP3). There is a ClinVar entry for this variant (Variation ID: 526532 , 2-star review status) with 4 submitters classifying the variant as pathogenic (n=2) or likely pathogenic (n=2). In summary, this variant meets the criteria to be classified as likely pathogenic for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert panel (Specifications Version 2.0.0): PP4_moderate, PM3_strong, PM2_supporting, PP3. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on April 15, 2025)